A randomized, placebo controlled, double masked phase IB study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adults. [PDF]
PLoS ONE, 2011 Neurokinin-1 receptor (NK1R) antagonists have anti-HIV activity in monocyte-derived macrophages, decrease CCR5 expression and improve natural killer cell function ex vivo.
Pablo Tebas +8 more
doaj +5 more sources
Efficacy of the oral neurokinin-1 receptor antagonist aprepitant administered with ondansetron for the prevention of postoperative nausea and vomiting [PDF]
Korean Journal of Anesthesiology, 2013 Background5-HT3 receptor antagonist, dexamethasone and droperidol were used for the prevention of postoperative nausea and vomiting (PONV). Recently, neurokinin-1 (NK1) antagonist has been used for PONV.
Chae Seong Lim +6 more
doaj +5 more sources
The neurokinin-1 receptor antagonist aprepitant in co-morbid alcohol dependence and posttraumatic stress disorder: a human experimental study [PDF]
Psychopharmacology, 2014 Posttraumatic stress disorder (PTSD) and alcoholism are frequently comorbid, suggesting the possibility of overlapping neural substrates. The neurokinin 1 (NK1) receptor for substance P (SP) has been implicated in both stress- and alcohol-related behaviors.
Kwako LE +9 more
openaire +3 more sources
Chemotherapy-Induced Nausea and Vomiting: The Role of Aprepitant
Middle East Journal of Cancer, 2011 Antiemetics are given to cancer patients prior to their chemotherapy sessions to protect them from nausea and vomiting induced by chemotherapy. The responsible health care team member will choose the type of antiemetic required to prevent the patient ...
Muath Mohammed Abu Hilal
doaj +1 more source
Biomedical Journal, 2016 Background: The purpose of this study was to evaluate the efficacy of combined treatment with the long-acting 5-hydroxytryptamine receptor-3 antagonist, palonosetron, the neurokinin-1 receptor antagonist, oral aprepitant, and dexamethasone as primary ...
Chan-Keng Yang +2 more
doaj +2 more sources
International Journal of Research in Hospital and Clinical Pharmacy, 2019 Nausea and emesis are two major concerns for patients undergoing chemotherapy for cancer. The 5HT3 receptors antagonist ondansetron is the major factor for preventing and treatment for CINV either alone or often is combination with dexamethasone. Even these treatment options exist, CINV remind as major adverse event for all chemotherapeutic agents. The
null Robin George +3 more
openaire +3 more sources
Proteomic and Phosphoproteomic Analysis Reveals that Neurokinin-1 Receptor (NK1R) Blockade with Aprepitant in Human Keratinocytes Activates a Distinct Subdomain of EGFR Signaling: Implications for the Anti-Pruritic Activity of NK1R Antagonists [PDF]
Medicines, 2019 Background: Epidermal growth factor receptor (EGFR) inhibitors can cause serious cutaneous toxicities, including pruritus and papulopustular acneiform skin eruptions. Increasingly, the neurokinin-1 receptor (NK1R) antagonist aprepitant is being utilized as an anti-pruritic agent in the treatment of EGFR-inhibitor induced pruritus.
Shawn G. Kwatra +10 more
openaire +5 more sources
Molecular and Clinical Oncology, 2019 Lung cancer (LC) is the leading cause of cancer death and is responsible for more than one-quarter (27%) of all cancer deaths. Non-small-cell LC (NSCLC) is the main histological subtype of LC and is the leading cause of mortalities associated with cancer.
Muñoz, Miguel +3 more
openaire +6 more sources
Medicine ScienceSubstance P (SP) is a peptide neurotransmitter that plays a role in pain transmission, stress, inflammation, and emesis through neurokinin-1 receptor (NK-1R).
Selma Cirrik +3 more
doaj +2 more sources
Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy.
PLoS ONE, 2010 BackgroundChronic pruritus is a global clinical problem with a high impact on the quality of life and lack of specific therapies. It is an excruciating and frequent symptom of e.g.
Sonja Ständer +4 more
doaj +2 more sources